Crizotinib + Pembrolizumab
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALK-positive Advanced NSCLC
Conditions
ALK-positive Advanced NSCLC
Trial Timeline
Oct 1, 2015 → Dec 1, 2017
NCT ID
NCT02511184About Crizotinib + Pembrolizumab
Crizotinib + Pembrolizumab is a phase 1 stage product being developed by Merck for ALK-positive Advanced NSCLC. The current trial status is terminated. This product is registered under clinical trial identifier NCT02511184. Target conditions include ALK-positive Advanced NSCLC.
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02511184 | Phase 1 | Terminated |
Competing Products
9 competing products in ALK-positive Advanced NSCLC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceritinib (LDK378) + Nivolumab | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 27 |
| Ceritinib | Novartis | Phase 2 | 35 |
| ceritinib + warfarin + midazolam | Novartis | Phase 1 | 29 |
| PF-02341066 + Rifampin + Itraconazole | Pfizer | Phase 1 | 29 |
| Lortlatinib | Pfizer | Pre-clinical | 26 |
| Lorlatinib | Pfizer | Phase 2 | 31 |
| crizotinib + alectinib + brigatinib + ceritinib + lorlatinib | Pfizer | Pre-clinical | 26 |
| PF-06463922 + Crizotinib | Pfizer | Phase 1/2 | 32 |